Isotonitazene
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Isotonitazene is a synthetic opioid of the benzimidazole class. It is structurally related to fentanyl but approximately four times more potent in animal models.[1] Isotonitazene is a full agonist at µ-opioid receptors, producing its effects by powerfully suppressing pain signaling and depressing respiratory drive.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, fentanyl, heroin +4 moremorphine, fentanyl, heroin, oxycodone, hydromorphone, methadone, all MOR full agonists show less
First identified on European online drug markets in 2019,[2] isotonitazene was the first of the "nitazene" compounds — a family abandoned by pharmaceutical researchers in the 1960s for being too dangerous[3][4] — to reach unregulated supply. It became the most prevalent novel synthetic opioid in US forensic casework during 2020–2021[5] and catalyzed the emergence of over 20 related analogues across Europe by 2024.[6]
Subjective effects include pain suppression, euphoria, sedation, pupil constriction, and respiratory depression. The experience is inferred entirely from its receptor pharmacology — no controlled human studies exist — and clinical case reports describe only loss of consciousness and respiratory failure.[7][8] Nausea and constipation are expected unsought effects consistent with the opioid class.
Isotonitazene carries extreme abuse liability and acute lethality at blood concentrations below one billionth of a gram per milliliter.[9] Standard naloxone doses may fail to reverse overdose because the compound dissociates from receptors unusually slowly,[10] and its primary metabolite is even more potent than the parent drug.[9][11] No controlled human data of any kind have been published — the current understanding rests entirely on animal pharmacology, forensic casework, and emergency department reports.
History[edit]
Discovery
The nitazene class — formally the 2-benzylbenzimidazole opioids — was first synthesized in the late 1950s at the Swiss pharmaceutical company Ciba.[12] Hundreds of analogues were prepared and tested for painkilling potency, but the entire family was shelved: the gap between an effective dose and a lethal dose was too narrow for safe medical use.[3][4] The compounds sat untouched in the scientific literature for sixty years.
Market emergence
Isotonitazene broke that silence in 2019, when Belgian researchers at Ghent University identified it in a sample sold online under the name "etonitazene" — a mislabeling, since isotonitazene is a distinct positional isomer.[2] The product was nearly pure: greater than 95% by GC-MS, greater than 98% by NMR.[7][2] Blanckaert and colleagues published the first full chemical and biological characterization in 2020, alerting forensic and toxicology communities to a dangerously potent new opioid.[2]
Scheduling and spread
Fatalities accumulated rapidly. The US Drug Enforcement Administration issued emergency Schedule I placement in August 2020,[13] and the United Nations placed it under international control in 2021.[14] Isotonitazene was the most prevalent novel synthetic opioid in US forensic casework during 2020–2021,[5] but its market share dropped sharply after scheduling — immediately replaced by metonitazene and other analogues, illustrating the cycle of substitution that defines novel opioid markets.[6][15]
The name "nitazene" derives from the 5-nitro group on the benzimidazole ring that is essential to the class's potency — a pharmacophore-based nickname that stuck in forensic literature and eventually migrated to street parlance. Isotonitazene itself has no established street names; it typically appears in supply chains disguised as other opioids or sold under its chemical name on online markets. The original 2019 sample was mislabeled as "etonitazene",[2] and a later drug-checking sample labeled as isotonitazene actually contained N-desethyl etonitazene — a different compound entirely.[16] This pattern of mislabeling is characteristic of the nitazene market.
Chemistry[edit]
Structural class
Isotonitazene belongs to the 2-benzylbenzimidazole opioid class, commonly called the "nitazenes." The core structure is a benzimidazole ring with a benzyl group at C-2 and an aminoethyl chain at N-1. It is a positional isomer of the parent compound etonitazene, differing only in the alkoxy group on the pendant benzyl ring: isotonitazene carries a 4-isopropyloxy group where etonitazene has a 4-ethoxy group.[2][6]
Molecular properties
| Molecular formula | C₂₃H₃₀N₄O₃ |
| Molecular weight | 410.5 g/mol |
The compound does not contain a defined chirality center, and no published data address stereoisomeric forms.
Key structural features
Three elements govern isotonitazene's pharmacological profile[2][6]:
- A 5-nitro group on the benzimidazole ring, essential for potency. Removing this group dramatically reduces opioid receptor binding across all tested nitazene analogues.[9]
- A 4-isopropyloxybenzyl group at C-2. The length of the alkoxy chain at this position is a principal determinant of potency within the class — isopropoxy (isotonitazene), ethoxy (etonitazene), and methoxy (metonitazene) define distinct potency tiers.[17]
- An N,N-diethylaminoethyl chain at N-1. Loss of one ethyl group through metabolism produces N-desethyl isotonitazene, which unusually exceeds the parent compound in opioid receptor potency.[9][11] This metabolite has also appeared as a standalone product on drug markets.[16]
Physical properties
Isotonitazene has been encountered as a white to off-white powder. Early market samples were essentially undiluted pure compound.[7][2] No published data exist for melting point, solubility, or stability under storage conditions.
Postmortem stability is a documented concern: nitazenes may degrade in biological specimens before toxicological analysis, potentially causing fatality counts to be underestimated.[18]
Pharmacology[edit]
Mechanism of action
Isotonitazene is a full agonist at the µ-opioid receptor (μ-opioid) with exceptionally high binding affinity and efficacy comparable to the strongest known reference opioids.[1][2] It binds MOR far more tightly than it binds kappa or delta opioid receptors, making its pharmacology overwhelmingly µ-selective.[11]
A critical feature is how slowly isotonitazene releases from the receptor once bound. This slow dissociation reduces the ability of naloxone — a competitive antagonist — to displace it, providing a mechanistic explanation for clinical reports of incomplete overdose reversal at standard naloxone doses.[10][8][3]
In rat analgesic testing, isotonitazene was approximately 3.7 times more potent than fentanyl and roughly 1,500 times more potent than morphine.[1]
Pharmacokinetics
No controlled human pharmacokinetic studies have been published. Duration of action, oral bioavailability, plasma half-life, and clearance are entirely unknown in humans. All pharmacokinetic inference comes from animal data and postmortem tissue analysis.
The primary metabolic pathways are removal of an ethyl group (N-deethylation) and cleavage of the isopropyl ether (O-dealkylation), producing at least 12 identified metabolites.[19] The major circulating metabolite, N-desethyl isotonitazene, is more potent at the µ-opioid receptor than isotonitazene itself[9][11] — an unusual and dangerous property that means the body's own processing of the drug can intensify its effects.
In postmortem cases, the highest concentrations of isotonitazene were found in brain and lung tissue, consistent with the central nervous system depression and respiratory failure that constitute the primary cause of death.[7][20] Liver concentrations were unexpectedly low compared to other opioids, complicating forensic interpretation.[7]
Neuroscience[edit]
Where it acts
Isotonitazene activates the brain's reward circuitry at extraordinarily low doses. Through µ-opioid receptor agonism in the ventral tegmental area, it triggers dopamine release in the nucleus accumbens — the core neural substrate of reward — at levels comparable to morphine given at 100-fold higher doses.[1] This dopaminergic surge drives the reinforcing properties confirmed by animal studies showing conditioned place preference at very low doses.[21]
The lethal mechanism centers on brainstem respiratory nuclei. Isotonitazene's slow release from µ-opioid receptors in these areas prolongs respiratory suppression and reduces the window for naloxone rescue.[10][4][22]
Why it matters
The disproportionate dopamine release relative to dose supports the incentive salience model of addiction: isotonitazene may generate intense motivational drive ("wanting") at doses far below those of conventional opioids.[1] Combined with its high efficacy and an active metabolite that exceeds the parent compound's potency,[9][11] this creates conditions for rapid reinforcement escalation and severe dependence.
The human dose-response relationship is entirely unknown — animal potency ratios cannot be directly extrapolated. How much of the compound's in vivo toxicity is driven by the parent drug versus the more potent N-desethyl metabolite remains unquantified. Whether nitazenes produce long-term changes in reward circuitry structure, as other potent µ-opioid agonists do, has not been investigated.
Subjective Effects[edit]
No controlled human studies have been published for isotonitazene. The entire experiential profile is inferred from µ-opioid receptor pharmacology: as a high-efficacy full agonist roughly 1,500 times more potent than morphine,[1] it is expected to produce the full opioid constellation — warmth, pain erasure, heavy sedation, and narrowed awareness — but at doses so small they cannot be reliably measured without laboratory equipment. The presence of a more potent active metabolite introduces an additional layer of unpredictability, as the body's processing of the drug may intensify or extend effects beyond what the initial dose would suggest.[9][11]
Compared to fentanyl, isotonitazene is approximately 3.7 times more potent in animal models,[1] with the critical added risks of impaired naloxone reversibility[10] and an active metabolite that fentanyl lacks. Clinical case reports describe only two outcomes: profound loss of consciousness and respiratory failure[7][8] — no reports of graded, dose-titrated experiences exist in the published literature.
Effect Grid
Pronounced euphoria, strong pain suppression, and marked sedation dominate the experience. Cognitive euphoria merges with significant thought deceleration, emotional suppression, and cognitive impairment. Focus suppression and motivation suppression are prominent. The characteristic opioid 'nod' — oscillation between wakefulness and a dream-like sedated state — may occur.
Respiratory depression becomes clinically significant at this level. Bodily heaviness is pronounced, with strong muscle relaxation, constipation, nausea, and motor control impairment. Pupil constriction is marked. Body high and tactile euphoria are intense.
Standard naloxone dosing may be insufficient to reverse respiratory depression at this level due to slow receptor dissociation kinetics. The compulsive redosing urge is strong.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sedation · Bodily heaviness · Muscle relaxation · Breathing alteration · Constipation · Physical fatigue · Nausea · Tactile euphoria · Appetite suppression · Dizziness · Sexual arousal suppression · Spontaneous body sensations · Dry mouth · Excessive sweating · Temperature dysregulation · Vomiting · Yawning · Nystagmus (eye wobbles) · Salivation · Watery eyes · Bodily dissociation
Breathing alteration · Constipation · Physical fatigue · Nausea · Tactile euphoria · Appetite suppression · Dizziness · Sexual arousal suppression · Spontaneous body sensations · Dry mouth · Excessive sweating · Vomiting · Yawning · Nystagmus (eye wobbles) · Salivation · Watery eyes · Bodily dissociation
Focus suppression · Analysis suppression · Information processing suppression · Motivation suppression · Thought deceleration · Language suppression · Confusion · Thought disorganization · Delirium
Motivation suppression · Thought deceleration · Language suppression · Confusion · Thought disorganization
Disinhibition
Timeline
Near-immediate awareness of warmth and altered sensorium following injection. Effects begin within seconds due to direct vascular delivery of a sub-nanomolar-potent MOR agonist.
Rapid intensification of sedation, euphoria, and pain suppression. Respiratory rate begins to decrease. Pupil constriction becomes apparent.
Maximum intensity of MOR-mediated effects: profound sedation, strong euphoria, complete pain suppression. Respiratory depression is at its most severe. Risk of unconsciousness and respiratory arrest is highest during this phase.
Sustained but gradually diminishing sedation and euphoria. Respiratory depression may persist or worsen as the active metabolite N-desethyl isotonitazene accumulates. The 'nod' state may occur.
Slow return toward baseline. Residual sedation, pupil constriction, and mild respiratory depression persist. The active metabolite may prolong this phase unpredictably beyond typical fentanyl resolution times.
Lingering drowsiness, mild constipation, and residual cognitive slowing. Subclinical respiratory depression may persist due to active metabolite.
⚠ Do not drive or operate machinery for at least 12 hours after exposure — residual impairment from both parent compound and active metabolite may persist well beyond subjective return to baseline.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · fentanyl · heroin
Toxicity
Acute toxicity
Isotonitazene is acutely lethal at blood concentrations below one billionth of a gram per milliliter. Fatal cases have been documented at femoral blood concentrations as low as 1.20 ng/mL with no other intoxicant present,[7] and sub-ng/mL levels have been reported in broader forensic series.[9] No human lethal dose or therapeutic index has been established — the compound was never developed for medical use.
Death occurs through severe respiratory depression via µ-opioid receptor activation in brainstem respiratory centers.[4][22] The compound's slow release from opioid receptors prolongs the period of respiratory compromise.[10]
The active metabolite N-desethyl isotonitazene is more potent than the parent compound,[9][11] raising the possibility of delayed or worsening toxicity as the body metabolizes the drug after initial exposure.
Fatality data
Documented deaths span multiple countries:
- United States (2020–2021): 144 postmortem detections — the most prevalent novel synthetic opioid in forensic casework during that period[5]
- Switzerland (2021): 3 deaths from pure compound as the sole intoxicant[7]
- France (2023): 9 cases over six weeks including 1 death and 1 intensive care admission[8]
- Norway (2021–2024): 36 nitazene-related deaths; over 90% involved multiple substances[15]
- Sweden (2020–2024): 57 nitazene autopsy cases across multiple analogues[23]
These figures are likely underestimates. Nitazenes may degrade in biological specimens before toxicological analysis, producing false-negative results and systematically undercounting deaths.[18]
Detection limitations
Standard urine drug screens — including fentanyl test strips — do not detect isotonitazene or other nitazenes.[4][22] The sub-ng/mL concentrations in biological samples require specialized laboratory mass spectrometry for reliable detection.[4][22][24] This means clinical and forensic cases may go unrecognized unless isotonitazene is specifically tested for.
Product mislabeling adds further danger: the original identification found isotonitazene sold as "etonitazene",[2] and a later drug-checking sample labeled as isotonitazene actually contained a different potent compound.[16]
Psychological risks
No published data address isotonitazene's psychological risk profile specifically. Clinical case reports describe only profound unconsciousness — patients are not communicative during documented presentations.[7][8]
As a potent µ-opioid agonist, isotonitazene is expected to carry the psychological risks common to the opioid class: cognitive impairment during intoxication, intense craving, compulsive use patterns, and dysphoria during withdrawal. The extreme potency and lack of safe dose titration may produce a uniquely compressed risk curve in which the margin between desired effects and life-threatening toxicity is functionally nonexistent for unsupervised use. inferred
Tolerance and dependence
No published human tolerance or dependence data exist for isotonitazene.
Cross-tolerance with other µ-opioid agonists (morphine, Fentanyl, Heroin) is expected based on shared receptor pharmacology, though the rate and extent of tolerance development are unknown. inferred
Animal data provide strong evidence for high abuse liability. Mice developed conditioned place preference at very low doses, with concurrent dopamine elevation in the reward center of the brain.[21] The magnitude of dopamine release was comparable to morphine at 100-fold higher doses.[1] Investigators concluded that isotonitazene carries a high risk of forming drug dependence via the dopaminergic reward system.[21]
No human withdrawal syndrome has been described. Class inference predicts a withdrawal characterized by dysphoria, anxiety, pain hypersensitivity, sweating, rapid heart rate, gastrointestinal distress, and insomnia. Duration and severity are unknown. inferred
Drug interactions
Benzodiazepines
The most dangerous interaction. Norwegian forensic data show that over 90% of nitazene-related deaths involved multiple substances, with designer benzodiazepines (especially flualprazolam) present in 50% of cases.[15] The combination produces multiplicative respiratory depression: benzodiazepines suppress breathing through one mechanism while isotonitazene suppresses it through another.
Other opioids
Additive respiratory depression through the same receptor pathway. Polydrug opioid use is documented in postmortem case series.[25][5]
Alcohol
Synergistic central nervous system and respiratory depression, documented in polydrug fatality patterns.[15]
Naloxone
Naloxone's effectiveness is reduced by isotonitazene's slow receptor dissociation. Standard doses may fail; high-dose or repeated administration is required.[10][8][3]
MAO inhibitors
Co-administration of opioids with monoamine oxidase inhibitors carries risk of dangerous reactions and potentiated central nervous system depression across the opioid class. No isotonitazene-specific data exist. inferred
Contraindications
No isotonitazene-specific contraindication data have been published. The following are inferred from µ-opioid agonist pharmacology and documented polydrug fatality patterns. inferred
- Concurrent benzodiazepine use (absolute): Multiplicative respiratory depression; primary driver of polydrug nitazene fatalities.[15]
- Concurrent opioid use (absolute): Additive respiratory depression.[25]
- Concurrent alcohol use (absolute): Synergistic respiratory and central nervous system depression.[15]
- Concurrent MAO inhibitor use (absolute): Risk of dangerous reactions and potentiated depression; class-level opioid contraindication. inferred
- Respiratory compromise (absolute): Asthma, chronic lung disease, sleep apnea, or any condition reducing baseline breathing capacity increases the risk of fatal respiratory depression. inferred
- Liver impairment (relative): Reduced metabolism could increase exposure to both parent compound and active metabolite. inferred
- Kidney impairment (relative): Impaired excretion of metabolites may prolong activity. inferred
Harm Reduction[edit]
Forms & Identification
Isotonitazene has appeared as a white to off-white powder, sometimes at near-pure concentrations.[7][2] It cannot be distinguished from other white powdered opioids by appearance alone, and it has been sold under incorrect names — including as "etonitazene"[2] and in at least one case where a sample labeled as isotonitazene actually contained a different compound entirely.[16]
Standard immunoassay drug tests and fentanyl test strips do not detect isotonitazene or other nitazenes.[4][22] Only laboratory-grade mass spectrometry can reliably identify this compound. A negative fentanyl strip result provides no assurance that a sample is free of nitazenes.
Guidelines
- Never use alone. A sober observer trained in overdose response should be present at all times.
- Carry naloxone — multiple doses. Standard single-dose naloxone may be insufficient for nitazene overdoses.[10][8]
- Assume any unidentified white powder could contain nitazenes. A negative fentanyl test strip does not rule them out.[4]
- If drug-checking services are available, use them. Laboratory analysis is the only reliable identification method.
- Do not combine with benzodiazepines, alcohol, other opioids, or any sedating substance. Over 90% of nitazene fatalities involve polydrug combinations.[15]
- No dose can be assumed safe. There is no published human dose-response curve and no therapeutic index.
Set & Setting
The concept of dose titration — starting low and increasing gradually — is functionally impossible with isotonitazene due to its microgram-level activity and the lack of any characterized human dose-response curve. There is no established safe dose, and the margin between effect and death cannot be navigated by feel.
Anyone in proximity to isotonitazene use should be trained in overdose recognition and naloxone administration. Use should never occur alone.
Aftercare & integration. Survivors of isotonitazene exposure — whether intentional or accidental — should be monitored in a medical setting for an extended period. The slow receptor dissociation and active metabolite mean that respiratory depression can recur hours after initial reversal.
Any exposure to isotonitazene, even a non-fatal one, should prompt an honest assessment of opioid use patterns and access to support. If the exposure was unintentional (contaminated supply), this information should be reported to local drug-checking or early warning services where available.
Recovery & Support
Isotonitazene dependence, like all potent opioid dependence, carries a high risk of fatal relapse. Evidence-based opioid use disorder treatments — including buprenorphine and methadone maintenance — dramatically reduce mortality risk and are the standard of care.
Peer support organizations, crisis lines, and medication-assisted treatment programs are available in most jurisdictions. Seeking help is not a failure — potent synthetic opioid dependence is a medical condition with effective treatments.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Slow, shallow, or stopped breathing. Blue or gray lips, fingertips, or skin. Gurgling or choking sounds. Pinpoint pupils. Unresponsive to voice or pain. Limpness. Any of these after suspected opioid exposure is a medical emergency.
Immediate steps
- 1. Call emergency services immediately. Do not wait to see if the person improves.
- 2. Administer naloxone if available. Use the highest available dose. Be prepared to give additional doses — standard naloxone may not fully reverse isotonitazene.[10][3]
- 3. Place the person in the recovery position (on their side) to prevent choking.
- 4. Begin rescue breathing if the person is not breathing and you are trained to do so.
- 5. Stay with the person. Naloxone wears off faster than isotonitazene — breathing may stop again after apparent recovery.
- 6. Do not induce vomiting. Do not leave the person alone.
What to tell the dispatcher
State that the person is unresponsive and not breathing or breathing very slowly. Say "possible opioid overdose" and mention nitazene if known. Provide the amount taken if known, when it was taken, and any other substances involved. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents
Naloxone (Narcan) is the standard opioid overdose reversal agent but has reduced effectiveness against isotonitazene due to the compound's slow release from opioid receptors.[10] Multiple doses, higher-than-standard doses, or continuous intravenous infusion may be required.[3][8] Even after apparent reversal, monitor closely for re-sedation as naloxone's duration of action is shorter than isotonitazene's.
Legal Status[edit]
Isotonitazene is subject to international controls and has been independently scheduled in multiple jurisdictions. The WHO Expert Committee on Drug Dependence conducted a critical review and recommended scheduling,[26] and the United Nations Commission on Narcotic Drugs placed it under the 1961 Single Convention in 2021.[14] The regulatory response was notably rapid, driven by the volume of fatal outcomes within months of the compound's market appearance.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency temporary scheduling August 2020;[13] permanent Schedule I placement November 2021[27] |
| United Kingdom | Class A (Misuse of Drugs Act 1971), Schedule 1 (MDR 2001) | Following ACMD advice in 2022; maximum penalties for Class A possession and supply apply[28] |
| France | Narcotic (classified 2021) | Classified before first domestic detection; first French cases identified March 2023[8] |
| Canada | Controlled (Controlled Drugs and Substances Act) | Scheduled under federal narcotics controlscitation needed |
| European Union | Under EMCDDA intensive surveillance | Individual member state scheduling varies; 22 nitazene analogues identified in Europe by end of 2024[6] |
| Australia | Status not confirmed | Scheduling status could not be verified from sources reviewedcitation needed |
| International | Scheduled under 1961 Single Convention | CND 64th session (2021)[14] |
The pattern of rapid structural analog substitution following scheduling — isotonitazene's market prevalence dropping sharply after US Schedule I placement, with immediate replacement by metonitazene and other analogues[6][15] — illustrates a fundamental limitation of substance-specific scheduling for structurally flexible drug classes.
references
- [1] ^abcdefghDe Luca MA, Tocco G, Mostallino R, Laus A, Caria F, Musa A, Pintori N, Ucha M, Poza C, Ambrosio E, Di Chiara G, Castelli MP (2022) Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent mu-opioid receptor agonists. — Neuropharmacology doi:10.1016/j.neuropharm.2022.109263
- [2] ^abcdefghijklBlanckaert P, Cannaert A, Van Uytfanghe K, Hulpia F, Deconinck E, Van Calenbergh S, Stove C (2020) Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene. — Drug Testing and Analysis doi:10.1002/dta.2738
- [3]
- [4]
- [5] ^abcdPapsun DM, Krotulski AJ, Logan BK (2022) Proliferation of Novel Synthetic Opioids in Postmortem Investigations After Core-Structure Scheduling for Fentanyl-Related Substances. — The American Journal of Forensic Medicine and Pathology doi:10.1097/paf.0000000000000787
- [6]